WO2001060816A1
(en)
|
2000-02-17 |
2001-08-23 |
Amgen Inc. |
Kinase inhibitors
|
AU2003232960A1
(en)
|
2002-07-24 |
2004-02-09 |
University Of Cincinnati |
4-4(methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating mutated-ret kinase associated diseases
|
PT1696920E
(pt)
|
2003-12-19 |
2015-01-14 |
Plexxikon Inc |
Compostos e métodos para o desenvolvimento de moduladores de ret
|
US8227455B2
(en)
|
2005-04-18 |
2012-07-24 |
Rigel Pharmaceuticals, Inc. |
Methods of treating cell proliferative disorders
|
AP2358A
(en)
|
2005-05-09 |
2012-01-30 |
Achillion Pharmaceuticals Inc |
Thiazole compounds and methods of use.
|
US20100047777A1
(en)
|
2005-05-26 |
2010-02-25 |
The Johns Hopkins University |
Methods for identifying mutations in coding and non-coding dna
|
WO2007023382A2
(en)
|
2005-08-25 |
2007-03-01 |
Pfizer Inc. |
Pyrimidine amino pyrazole compounds, potent kinase inhibitors
|
WO2007087245A2
(en)
|
2006-01-24 |
2007-08-02 |
Merck & Co., Inc. |
Ret tyrosine kinase inhibition
|
CN104706637A
(zh)
|
2006-05-18 |
2015-06-17 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
WO2008061201A1
(en)
|
2006-11-15 |
2008-05-22 |
Rigel Pharmaceuticals, Inc. |
Methods for treating renal tumors using 2,4-pyrimidinediamine drug and prodrug compounds
|
WO2009003136A1
(en)
|
2007-06-26 |
2008-12-31 |
Rigel Pharmaceuticals, Inc. |
Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
|
KR20100031639A
(ko)
|
2007-07-09 |
2010-03-23 |
아스트라제네카 아베 |
증식성 질환의 치료용 삼중 치환된 피리미딘 유도체
|
EP2178861B1
(en)
|
2007-07-19 |
2014-08-20 |
Merck Sharp & Dohme Corp. |
Heterocyclic amide compounds as protein kinase inhibitors
|
WO2009100536A1
(en)
|
2008-02-15 |
2009-08-20 |
Methylgene Inc. |
Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
|
EP2313091A4
(en)
|
2008-07-14 |
2012-04-04 |
Univ Kingston |
PHARMACEUTICAL COMPOSITIONS WITH RET-HEMMERN AND METHOD FOR THE TREATMENT OF CANCER
|
WO2010111056A1
(en)
|
2009-03-24 |
2010-09-30 |
Banyu Pharmaceutical Co., Ltd. |
Novel aminopyridine derivatives having aurora a selective inhibitory action
|
JP2012529513A
(ja)
|
2009-06-08 |
2012-11-22 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
トリアジン誘導体類及びそれらの治療応用
|
WO2010144394A1
(en)
|
2009-06-09 |
2010-12-16 |
Abraxis Bioscience, Llc |
Benzyl substituted triazine derivatives and their therapeutical applications
|
EA201290255A1
(ru)
|
2009-10-30 |
2013-04-30 |
Ариад Фармасьютикалз, Инк. |
Способы и композиции для лечения рака
|
EP2498607B1
(en)
|
2009-11-13 |
2016-02-17 |
Genosco |
Kinase inhibitors
|
EP2740742B1
(en)
|
2011-08-04 |
2018-03-14 |
National Cancer Center |
Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene
|
AU2012298884B2
(en)
|
2011-08-23 |
2017-11-16 |
Foundation Medicine, Inc. |
Novel KIF5B-RET fusion molecules and uses thereof
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
US20130096136A1
(en)
|
2011-09-30 |
2013-04-18 |
Methylgene Inc. |
Inhibitors of Protein Tyrosine Kinase Activity
|
US10023855B2
(en)
|
2011-10-31 |
2018-07-17 |
Macrogen, Inc. |
Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
|
US8841450B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
EP2824099A4
(en)
|
2012-03-09 |
2015-11-11 |
Carna Biosciences Inc |
NOVEL TRIAZINE DERIVATIVE
|
JP2015109806A
(ja)
|
2012-03-22 |
2015-06-18 |
アステラス製薬株式会社 |
新規ret融合体の検出法
|
JP6175672B2
(ja)
|
2012-04-25 |
2017-08-09 |
ラクオリア創薬株式会社 |
Ttx−s遮断薬としてのピロロピリジノン誘導体
|
WO2013170159A1
(en)
|
2012-05-10 |
2013-11-14 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
PT2872491T
(pt)
|
2012-07-11 |
2021-08-05 |
Blueprint Medicines Corp |
Inibidores do recetor do fator de crescimento de fibroblastos
|
EP2878672A4
(en)
|
2012-07-26 |
2016-02-17 |
Nat Cancer Ct |
FUSIONSGEN OF CEP55-GEN AND RET-GEN
|
EP2892532B1
(en)
|
2012-09-07 |
2019-02-13 |
Exelixis, Inc. |
Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
|
EP2902029B1
(en)
|
2012-09-25 |
2018-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Ret inhibitor
|
JP6326057B2
(ja)
|
2012-11-07 |
2018-05-16 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
置換ピリミジニルおよびピリジニル−ピロロピリジノン、これらの調製のための方法、およびキナーゼ阻害剤としてのこれらの使用
|
TWI629266B
(zh)
|
2012-12-28 |
2018-07-11 |
藍印藥品公司 |
纖維母細胞生長因子受體之抑制劑
|
EA027861B1
(ru)
|
2013-02-25 |
2017-09-29 |
Бристол-Майерс Сквибб Компани |
C-3 алкил- и алкенилмодифицированные производные бетулиновой кислоты или их фармацевтические соли, противовирусная фармацевтическая композиция и фармацевтическая композиция для лечения вич на их основе
|
WO2014160521A1
(en)
|
2013-03-15 |
2014-10-02 |
Blueprint Medicines Corporation |
Piperazine derivatives and their use as kit modulators
|
PT2970191T
(pt)
|
2013-03-15 |
2017-03-23 |
Glaxosmithkline Ip Dev Ltd |
Derivados de piridina como inibidores da quinase rearranjada durante transfecção(ret)
|
WO2014147640A2
(en)
|
2013-03-19 |
2014-09-25 |
Glenmark Pharmaceuticals Limited; Glenmark Generics Limited |
Process for the preparation of anagliptin
|
WO2015006875A1
(en)
|
2013-07-18 |
2015-01-22 |
Methylgene Inc. |
Process for the preparation of substituted pyrimidines
|
TW201542825A
(zh)
|
2013-08-20 |
2015-11-16 |
Nat Cancer Ct |
在肺癌辨識出的新穎融合基因
|
US9334263B2
(en)
|
2013-10-17 |
2016-05-10 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
PL3057969T3
(pl)
|
2013-10-17 |
2018-11-30 |
Blueprint Medicines Corporation |
Kompozycje użyteczne do leczenia zaburzeń związanych z KIT
|
EP3060560A1
(en)
|
2013-10-25 |
2016-08-31 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
GB201321146D0
(en)
|
2013-11-29 |
2014-01-15 |
Cancer Rec Tech Ltd |
Quinazoline compounds
|
WO2015108992A1
(en)
|
2014-01-15 |
2015-07-23 |
Blueprint Medicines Corporation |
Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
|
WO2016022569A1
(en)
|
2014-08-04 |
2016-02-11 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
DK3191450T3
(da)
|
2014-09-10 |
2019-05-20 |
Glaxosmithkline Ip Dev Ltd |
Pyridonderivater som kinasehæmmere omarrangeret under transfektion (ret)
|
MX2017003118A
(es)
|
2014-09-10 |
2018-05-07 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret).
|
PL3218378T3
(pl)
|
2014-11-14 |
2020-10-19 |
Nerviano Medical Sciences S.R.L. |
Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
|
WO2016127074A1
(en)
|
2015-02-06 |
2016-08-11 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
|
CN104844567B
(zh)
|
2015-04-23 |
2017-03-29 |
暨南大学 |
一种中间体1‑(3‑氯‑2‑吡啶基)‑3‑溴‑1h‑5‑吡唑甲酸的合成方法
|
CA2992586A1
(en)
|
2015-07-16 |
2017-01-19 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
|
JP2018521076A
(ja)
|
2015-07-24 |
2018-08-02 |
ブループリント メディシンズ コーポレイション |
Kit及びpdgfrに関連する疾病を治療するのに有用な化合物
|
CN108137607B
(zh)
|
2015-08-26 |
2021-04-06 |
缆图药品公司 |
适用于治疗与ntrk相关的病症的化合物和组合物
|
CN105255927B
(zh)
|
2015-09-30 |
2018-07-27 |
温州医科大学附属第一医院 |
一种kiaa1217-ret融合基因
|
CN108884139A
(zh)
|
2015-11-02 |
2018-11-23 |
戊瑞治疗有限公司 |
Cd80胞外域多肽及其在癌症治疗中的用途
|
CN111423416B
(zh)
|
2015-11-02 |
2023-05-26 |
缆图药品公司 |
Ret的抑制剂
|
BR112018008908A2
(pt)
|
2015-11-02 |
2018-11-27 |
Janssen Pharmaceutica Nv |
anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
|
SG10201912607SA
(en)
|
2015-11-19 |
2020-02-27 |
Blueprint Medicines Corp |
Compounds and compositions useful for treating disorders related to ntrk
|
CA3007644A1
(en)
|
2015-12-11 |
2017-06-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
|
WO2017145050A1
(en)
|
2016-02-23 |
2017-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
|
WO2017161269A1
(en)
|
2016-03-17 |
2017-09-21 |
Blueprint Medicines Corporation |
Inhibitors of ret receptor tyrosine kinases
|
BR112018070163A2
(pt)
|
2016-04-01 |
2019-01-29 |
Signal Pharm Llc |
compostos de aminopurina substituída, composições e métodos de tratamento
|
EP4104837A3
(en)
|
2016-04-15 |
2023-04-26 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
JP6943876B2
(ja)
|
2016-04-15 |
2021-10-06 |
キャンサー・リサーチ・テクノロジー・リミテッドCancer Research Technology Limited |
Retキナーゼ阻害剤としての複素環化合物
|
HUE063042T2
(hu)
|
2016-04-15 |
2023-12-28 |
Blueprint Medicines Corp |
Az aktivin receptorszerû kináz inhibitorai
|
US10227329B2
(en)
|
2016-07-22 |
2019-03-12 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
WO2018022761A1
(en)
|
2016-07-27 |
2018-02-01 |
Blueprint Medicines Corporation |
Substituted cyclopentane-amides for treating disorders related to ret
|
WO2018049233A1
(en)
|
2016-09-08 |
2018-03-15 |
Nicolas Stransky |
Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
|
JP2018052878A
(ja)
|
2016-09-29 |
2018-04-05 |
第一三共株式会社 |
ピリジン化合物
|
CN106749231B
(zh)
|
2016-10-09 |
2019-03-01 |
南京纳丁菲医药科技有限公司 |
萘啶化合物和药物组合物及它们的应用
|
TWI704148B
(zh)
*
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
JOP20190077A1
(ar)
|
2016-10-10 |
2019-04-09 |
Array Biopharma Inc |
مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
|
US10799503B2
(en)
|
2016-12-01 |
2020-10-13 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
US11168090B2
(en)
|
2017-01-18 |
2021-11-09 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
WO2018183712A1
(en)
|
2017-03-31 |
2018-10-04 |
Blueprint Medicines Corporation |
Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
US20210290620A1
(en)
*
|
2017-05-15 |
2021-09-23 |
Blueprint Medicines Corporation |
Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
|
ES2968421T3
(es)
|
2017-06-23 |
2024-05-09 |
San Diego State Univ Research Foundation |
Atropisomerismo para la selectividad potenciada de inhibidor de cinasa
|
CN109180677A
(zh)
|
2017-06-30 |
2019-01-11 |
厦门大学 |
取代芳基醚类化合物、其制备方法、药用组合物及其应用
|
ES2924548T3
(es)
|
2017-07-07 |
2022-10-07 |
Nipd Genetics Public Company Ltd |
Análisis paralelo multiplexado con enriquecimiento de blancos para la evaluación tumoral
|
CN107980784B
(zh)
|
2017-12-13 |
2020-05-26 |
中国农业大学 |
5-氨基吡唑类化合物在调节植物生长方面的应用
|
KR20200101358A
(ko)
|
2017-12-19 |
2020-08-27 |
터닝 포인트 테라퓨틱스, 인크. |
질병 치료용 대환식 화합물
|
JP7061195B2
(ja)
|
2018-01-18 |
2022-04-27 |
アレイ バイオファーマ インコーポレイテッド |
RETキナーゼ阻害剤としての置換ピラゾロ[3,4-d]ピリミジン化合物
|
WO2019143977A1
(en)
|
2018-01-18 |
2019-07-25 |
Array Biopharma Inc. |
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
|
CN111615514B
(zh)
|
2018-01-18 |
2022-10-11 |
奥瑞生物药品公司 |
作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
|
CN108341782A
(zh)
|
2018-03-30 |
2018-07-31 |
南京哈柏医药科技有限公司 |
3-氨基-5-甲基吡唑的合成工艺
|
EP3773589B1
(en)
|
2018-04-03 |
2023-11-01 |
Blueprint Medicines Corporation |
Ret inhibitor for use in treating cancer having a ret alteration
|
EP3833372A4
(en)
|
2018-08-10 |
2022-06-08 |
Blueprint Medicines Corporation |
TREATMENT OF EGFR MUTANT CANCER
|
CN111440151A
(zh)
|
2020-03-25 |
2020-07-24 |
魏威 |
制备抗肿瘤药普拉赛替尼的方法
|
CN111362923A
(zh)
|
2020-03-25 |
2020-07-03 |
魏威 |
制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法
|
JP2023527412A
(ja)
|
2020-05-29 |
2023-06-28 |
ブループリント メディシンズ コーポレイション |
プラルセチニブの固体形態
|
AU2021281283A1
(en)
|
2020-05-29 |
2022-12-15 |
Blueprint Medicines Corporation |
Pralsetinib pharmaceutical compositions
|
US20240059672A1
(en)
|
2020-12-04 |
2024-02-22 |
Blueprint Medicines Corporation |
Method of preparing pralsetinib
|